|Program||European Commission – Seventh Framework Programme
Marie Curie Actions— Industry-Academia Partnerships and Pathways (IAPP)
|Collaborative project||AutoFLOW – Automation of Flow Cytometric Analysis for Quality-Assured Follow-up Assessment to Guide Curative Therapy for Acute Lymphoblastic Leukaemia in Children|
|Project start||February 2014|
|Project duration||4 years|
|Funded by||European Commission|
Acute Lymphoblastic Leukaemia is the most frequent leukaemia entity in children and adolescents. Despite continued progress and refinement of therapeutic approaches, disease relapse due to insufficient extinction of leukaemic blasts still remains the number one cause of treatment failure. About 15-20% of paediatric patients with the disease still suffer from relapse. Flow cytometry (FCM) is one of the methodologies most useful in this respect, because it is widely available and applicable to most patients. These assessments are time-consuming and costly to be attained via staff-training, online support between twinning laboratories, and continued quality control.
To address this issue, AutoFLOW aims at developing an objective and automated tool for multi-parameter FCM data analysis with robust and reliable Minimal Residual Desease (MRD) quantification. The consortium aims at engaging professionals from the medical and ICT fields in a network where the exchange of knowledge will culminate in a valid solution for automated FCM analysis for clinical follow-up assessment of Acute Lymphoblastic Leukaemia (ALL). Additionally, AutoFLOW is expected to gain better career perspectives for the involved personnel and increase the competitiveness of the participating SMEs.
- Technische Universität Wien / Computer Vision Lab, Austria, www.technikum-wien.at
- CHARITE – Universitätsmedizin Berlin, Germany, www.charite.de
- Labdia Labordiagnostik GmbH, Austria, www.labdia.at
- CogVis GmbH, Austria, www.cogvis.at
- Infokom GmbH, Germany, www.infokom.de